{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:28Z","timestamp":1783024048306,"version":"3.54.6"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    We report a case of metastatic castration-resistant prostate carcinoma with discordant PSMA (prostate specific membrane antigen) expression\u2014\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT (positron emission tomography\/computed tomography) showed PSMA-avid skeletal metastases but nonavid liver lesions. The patient received\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 on compassionate grounds. Post-therapy imaging revealed radiotracer uptake in both skeletal and previously nonavid hepatic metastases, suggesting possible increased lesion amenability. This case highlights the dynamic nature of PSMA expression and the potential role of post-therapy scans in revealing responsive disease not visualized on baseline imaging.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006287","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:00:20Z","timestamp":1765897220000},"page":"e627-e628","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["PSMA Expression Heterogeneity in Metastatic Prostate Carcinoma: A Case of Discordant Liver Metastases on 68Ga PSMA PET\/CT Showing Uptake on Post\u2013Lu-177 PSMA Therapy Scan"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6846-8537","authenticated-orcid":false,"given":"Bela","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Baberwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"1373606","DOI":"10.3389\/fonc.2024.1373606","article-title":"Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review","volume":"14","author":"Yan","year":"2024","journal-title":"Front Oncol"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11864-024-01181-9","article-title":"Impact of PSMA PET on Prostate Cancer Management","volume":"25","author":"Weiner","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"R4-20260702","first-page":"1447","article-title":"Nomograms to predict outcome after Lutetium-177\u2013prostate-specific membrane antigen therapy in men with metastatic castration-resistant prostate cancer: an international, multicenter, retrospective study","volume":"62","author":"Gafita","year":"2021","journal-title":"J Nucl Med"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2967\/jnumed.122.265099","article-title":"PSMA-negative lesion progression under 177Lu-PSMA radioligand therapy","volume":"64","author":"Murthy","year":"2023","journal-title":"J Nucl Med"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:02:43Z","timestamp":1783022563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006287","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2025-08-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}